Comparative Pharmacology
Head-to-head clinical analysis: MIDOSTAURIN versus SPRYCEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDOSTAURIN versus SPRYCEL.
MIDOSTAURIN vs SPRYCEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Midostaurin is a multikinase inhibitor that targets FLT3 (FMS-like tyrosine kinase 3), KIT, PDGFRα/β, VEGFR2, and PKC. It inhibits FLT3 receptor signaling and downstream MAPK/ERK and PI3K/AKT pathways, inducing apoptosis in FLT3-mutated cells.
Dasatinib is a dual tyrosine kinase inhibitor targeting BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It binds to the ATP-binding site of BCR-ABL and inhibits proliferation and induces apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
50 mg orally twice daily with food for acute myeloid leukemia (AML) with FLT3 mutation; for advanced systemic mastocytosis, 100 mg orally twice daily.
100 mg orally once daily, with or without food.
None Documented
None Documented
Clinical Note
moderateMidostaurin + Digoxin
"Midostaurin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMidostaurin + Digitoxin
"Midostaurin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMidostaurin + Deslanoside
"Midostaurin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMidostaurin + Acetyldigitoxin
"Midostaurin may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life (t½) of midostaurin is approximately 20 hours (range 17–22 h) for the parent drug and slightly longer for its active metabolite CGP52421 (~30 h). This supports twice-daily dosing while maintaining steady-state concentrations.
Terminal elimination half-life is approximately 3–4 hours for dasatinib, with a longer half-life of 8–10 hours for its active metabolite; clinical context: supports twice-daily dosing.
Midostaurin is primarily eliminated via feces (approximately 95% of total radioactivity after a single 50 mg oral dose), with <5% excreted in urine. Biliary excretion is the major route for fecal elimination; unchanged midostaurin accounts for <10% of the dose, with the remainder as metabolites.
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor